89 related articles for article (PubMed ID: 20824955)
1. Effect of selected drugs on plasma asymmetric dimethylarginine (ADMA) levels.
Trocha M; Szuba A; Merwid-Lad A; Sozański T
Pharmazie; 2010 Aug; 65(8):562-71. PubMed ID: 20824955
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA).
Maas R
Vasc Med; 2005 Jul; 10 Suppl 1():S49-57. PubMed ID: 16444869
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric dimethylarginine--mechanisms and targets for therapeutic management.
Vladimirova-Kitova LG
Folia Med (Plovdiv); 2008; 50(1):12-21. PubMed ID: 18543783
[TBL] [Abstract][Full Text] [Related]
4. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.
Suda O; Tsutsui M; Morishita T; Tasaki H; Ueno S; Nakata S; Tsujimoto T; Toyohira Y; Hayashida Y; Sasaguri Y; Ueta Y; Nakashima Y; Yanagihara N
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1682-8. PubMed ID: 15217805
[TBL] [Abstract][Full Text] [Related]
5. ADMA: its role in vascular disease.
Cooke JP
Vasc Med; 2005 Jul; 10 Suppl 1():S11-7. PubMed ID: 16444864
[TBL] [Abstract][Full Text] [Related]
6. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension.
Ito A; Egashira K; Narishige T; Muramatsu K; Takeshita A
Jpn Circ J; 2001 Sep; 65(9):775-8. PubMed ID: 11548874
[TBL] [Abstract][Full Text] [Related]
7. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.
Pasini AF; Garbin U; Stranieri C; Boccioletti V; Mozzini C; Manfro S; Pasini A; Cominacini M; Cominacini L
Am J Hypertens; 2008 Nov; 21(11):1251-7. PubMed ID: 18772860
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.
Gamboa JL; Pretorius M; Sprinkel KC; Brown NJ; Ikizler TA
BMC Nephrol; 2015 Oct; 16():167. PubMed ID: 26494370
[TBL] [Abstract][Full Text] [Related]
9. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy.
Bełtowski J; Kedra A
Pharmacol Rep; 2006; 58(2):159-78. PubMed ID: 16702618
[TBL] [Abstract][Full Text] [Related]
10. The beneficial effects of angiotensin-converting enzyme inhibitors on serum asymmetric dimethylarginine levels in the patients with cardiovascular disease.
Celik T; Iyisoy A; Yuksel C; Jata B
Int J Cardiol; 2010 Jun; 142(1):107-9. PubMed ID: 19097650
[TBL] [Abstract][Full Text] [Related]
11. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity.
Garbin U; Pasini AF; Stranieri C; Manfro S; Boccioletti V; Cominacini L
Pharmacol Res; 2007 Dec; 56(6):515-21. PubMed ID: 17977009
[TBL] [Abstract][Full Text] [Related]
12. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2.
Hasegawa K; Wakino S; Tatematsu S; Yoshioka K; Homma K; Sugano N; Kimoto M; Hayashi K; Itoh H
Circ Res; 2007 Jul; 101(2):e2-10. PubMed ID: 17601800
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelium is the organ chiefly responsible for the catabolism of plasma asymmetric dimethylarginine--an explanation for the elevation of plasma ADMA in disorders characterized by endothelial dysfunction.
McCarty MF
Med Hypotheses; 2004; 63(4):699-708. PubMed ID: 15325021
[TBL] [Abstract][Full Text] [Related]
14. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
[TBL] [Abstract][Full Text] [Related]
15. Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease.
Schmitt B; Wolters M; Kressel G; Hülsmann O; Ströhle A; Kühn-Velten WN; Lichtinghagen R; Bub A; Barth SW; Stichtenoth DO; Hahn A
Atherosclerosis; 2007 Jul; 193(1):168-76. PubMed ID: 16876171
[TBL] [Abstract][Full Text] [Related]
16. Role of asymmetric dimethylarginine in inflammatory reactions by angiotensin II.
Chen MF; Xie XM; Yang TL; Wang YJ; Zhang XH; Luo BL; Li YJ
J Vasc Res; 2007; 44(5):391-402. PubMed ID: 17551258
[TBL] [Abstract][Full Text] [Related]
17. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine.
Thum T; Tsikas D; Stein S; Schultheiss M; Eigenthaler M; Anker SD; Poole-Wilson PA; Ertl G; Bauersachs J
J Am Coll Cardiol; 2005 Nov; 46(9):1693-701. PubMed ID: 16256870
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone lowers systemic asymmetric dimethylarginine by inducing dimethylarginine dimethylaminohydrolase in rats.
Wakino S; Hayashi K; Tatematsu S; Hasegawa K; Takamatsu I; Kanda T; Homma K; Yoshioka K; Sugano N; Saruta T
Hypertens Res; 2005 Mar; 28(3):255-62. PubMed ID: 16097370
[TBL] [Abstract][Full Text] [Related]
19. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine.
Holden DP; Cartwright JE; Nussey SS; Whitley GS
Circulation; 2003 Sep; 108(13):1575-80. PubMed ID: 12963642
[TBL] [Abstract][Full Text] [Related]
20. Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats.
De Gennaro Colonna V; Bonomo S; Ferrario P; Bianchi M; Berti M; Guazzi M; Manfredi B; Muller EE; Berti F; Rossoni G
Eur J Pharmacol; 2007 Feb; 557(2-3):178-85. PubMed ID: 17258196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
